{
    "root": "315b67a4-d076-3c01-e063-6394a90a172d",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Alprazolam",
    "value": "20250327",
    "ingredients": [
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "DOCUSATE SODIUM",
            "code": "F05Q2T2JA0"
        },
        {
            "name": "SODIUM BENZOATE",
            "code": "OJ245FE5EU"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "ALPRAZOLAM",
            "code": "YU55MQ3IZY"
        }
    ],
    "indications": "Alprazolam tablets are indicated for the: \n                  \n                     acute treatment of generalized anxiety disorder (GAD) in adults.\n                     treatment of panic disorder (PD), with or without agoraphobia in adults.",
    "contraindications": "Generalized Anxiety Disorder : ( 2.1 ) Recommended starting oral dosage is 0.25 mg to 0.5 mg three times daily. Dosage may be increased, at intervals of every 3 to 4 days, to a maximum recommended daily dose of 4 mg, given in divided doses. Use the lowest possible effective dose and frequently assess the need for continued treatment. Panic Disorder : Recommended starting oral dosage is 0.5 mg three times daily. The dosage may be increased at intervals of every 3 to 4 days in increments of no more than 1 mg per day. ( 2.2 ) When tapering, decrease dosage by no more than 0.5 mg every 3 days. Some patients may require an even slower dosage reduction. ( 2.3 , 5.2 ) See the Full Prescribing Information for the recommended dosage in geriatric patients, patients with hepatic impairment, and with use with ritonavir. ( 2.4 , 2.5 , 2.6 )",
    "warningsAndPrecautions": "Alprazolam Tablets USP are supplied in the following strengths and package configurations:\n  \n                     \n                     Alprazolam Tablets USP, 0.25 mgare white, oval shaped, uncoated tablets with breakline on one side debossed with ‘1’ and ‘8’ on either sides of the breakline and ‘Y’ on the other side.\n  \n                     \n                  Bottles of 1,000                        NDC 68071-3817-1\n  \n                     \n                     Store at20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].",
    "adverseReactions": "Alprazolam tablets are contraindicated in patients:\n                  \n                     with known hypersensitivity to alprazolam or other benzodiazepines. Angioedema has been reported\n  \n   [see\n   \n    Adverse Reactions (6.2)]\n  \n   .\n \n  \n                      taking strong cytochrome P450 3A (CYP3A) inhibitors (e.g., ketoconazole, itraconazole), except ritonavir\n  \n   [see\n   \n    Dosage and Administration (2.6),\n   \n    Warnings and Precautions (5.5),\n   \n    Drug Interactions (7.1)]"
}